Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia

Gynecologic Oncology Group (GOG)

Status and phase: Completed; Phase 3

Conditions: Good Prognosis Metastatic Gestational Trophoblastic Tumor; Uterine Corpus Choriocarcinoma; Non-Metastatic Gestational Trophoblastic Tumor; Hydatidiform Mole

Treatments: Drug: Methotrexate; Biological: Dactinomycin

Study type: Interventional

Funder types: NETWORK; NIH

Identifiers

NCT00003702

U10CA027469 (U.S. NIH Grant/Contract)

GOG-0174 (Other Identifier)

CDR0000066809

ECOG-G174

NCI-2011-02026 (Registry Identifier)

Details and patient eligibility

About

Randomized phase III trial to compare the effectiveness of methotrexate with that of dactinomycin in treating patients who have gestational trophoblastic neoplasia. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether methotrexate is more effective than dactinomycin in treating patients with gestational trophoblastic neoplasia.

Full description

OBJECTIVES:

I. Compare the efficacy of methotrexate vs dactinomycin, as measured by complete response rate, in patients with low-risk gestational trophoblastic neoplasia.

II. Compare the toxicity of these regimens in these patients. III. Determine whether the definition of persistent gestational trophoblastic neoplasia is accurate (as determined by the likelihood that the beta human chorionic gonadotropin [HCG] titer would decline on the day treatment is initiated).

OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive methotrexate intramuscularly once weekly in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive dactinomycin IV over 15 minutes every 2 weeks in the absence of disease progression or unacceptable toxicity. All patients continue on treatment until 1 beta human chorionic gonadotropin (HCG) titer is below the institutional normal. Patients then receive 1 additional consolidation treatment.

Patients are followed every 4 weeks for 1 year.

Enrollment: 240 patients

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Histologically proven low-risk gestational trophoblastic neoplasia (persistent hydatidiform mole or choriocarcinoma), defined as 1 of the following:

  • Less than 10% decrease in the beta human chorionic gonadotropin (HCG) titer over 3 weekly titers
  • Greater than 20% sustained rise in beta HCG titer over two consecutive weeks
  • Persistently elevated beta HCG titer more than 4 months after initial curettage (greater than 5 mIU/mL minimum)
  • Histologically proven nonmetastatic choriocarcinoma
  • Metastases to vagina, parametria, or lung (if no single pulmonary lesion is greater than 2 cm)

• WHO score 0-6 (not including blood group or CT lung)

• No histologically confirmed placental site pseudotumor

• Must have undergone at least 1 uterine curettage

• Previously untreated disease

• Performance status - GOG 0-2

• WBC at least 3,000/mm^3

• Granulocyte count at least 1,500/mm^3

• Platelet count at least 100,000/mm^3

• Bilirubin no greater than 1.5 times upper limit of normal (ULN)

• SGPT and SGOT no greater than 3 times ULN

• Alkaline phosphatase no greater than 3 times ULN

• No significant prior abnormal hepatic function

• Creatinine no greater than 2.0 mg/dL

• No significant prior abnormal renal function

• Not pregnant or nursing

• Fertile patients must use effective contraception during and for one year after study entry

• No other prior or concurrent malignancies within the past 5 years except nonmelanomatous skin cancer

• No prior chemotherapy for gestational trophoblastic neoplasia

• No concurrent curettage except as needed to control vaginal bleeding or to rule out placental site pseudotumor

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

240 participants in 2 patient groups

Arm I (methotrexate)

Experimental group

Description:

Patients receive methotrexate intramuscularly once weekly in the absence of disease progression or unacceptable toxicity. Patients continue on treatment until 1 beta HCG titer is below the institutional normal. Patients then receive 1 additional consolidation treatment.

Treatment:

Drug: Methotrexate

Arm II (dactinomycin)

Experimental group

Description:

Patients receive dactinomycin IV over 15 minutes every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients continue on treatment until 1 beta HCG titer is below the institutional normal. Patients then receive 1 additional consolidation treatment.

Treatment:

Biological: Dactinomycin